← board
IMMX
distress 4/10 · elevated risk$9.34-1%today-22% from 52w high
Lead: relapsed/refractory AL amyloidosis
Revenue
pre-revenue
Liquidity
$91M
Runway
2.8 yrs
Shares 1y
+89%
Price & events
+77.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.7%
1D
-7.2%
1W
-5.8%
1M
-8.2%
3M
+73.6%
6M
+222.1%
1Y
+344.8%
2Y
—
5Y
+154.5%
All
Overview
- Market Cap
- $508.20M
- Volume
- 29.68K
- 52 Week Range
- $1.96 – $12.02
- Total Shares
- 54.41M
- Float Shares
- 43.40M
- Short %
- 13.39%
- % Held by Insiders
- 17.56%
- % Held by Institutions
- 45.30%
- RVOL
- 0.01x
- Beta
- 0.09
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 6
- first half of 2027Guided 55%trial initiationsecondaryPhase 3NXC-201 · Plan to initiate multi-center, randomized Phase 3 trial.SEC 8-K
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)NXC-201 · BLA submissionSEC 8-K
- 2026Guided 40%readoutPhase 2NXC-201 · NEXICART-2 final readoutSEC 8-K
- following Q3 2026 topline resultsGuided 70%regulatory submissionFiled (NDA/BLA)NXC-201 · BLA submission planned after topline resultsSEC 8-K
- late September 2026Estimated 45%readoutPhase 2NXC-201 · Next NEXICART-2 update expected.SEC 8-K
- 2024-07-25partnershipNXC-201 · CIRM awarded $8 million grant to support NEXICART-2 clinical trial in AL Amyloidosis.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $20 (+112% upside) · 7 analysts
- 2026-06-18B of A SecuritiesBuy
- 2026-06-17LifeSci CapitalOutperform
- 2026-05-22HC Wainwright & Co.Buy
- 2026-03-30HC Wainwright & Co.Buy
- 2026-03-30MizuhoOutperform
- 2026-03-27CitizensMarket Outperform
Competitors — relapsed/refractory AL amyloidosis
- ABBVAbbVie Inc.$451.1B · D2
Recent news
- 2026-07-22IMMX Initiated Coverage by Needham -- Rating Set to Buy - GuruFocus
- 2026-07-22Immix Biopharma drops after chief medical officer terminated - MSN
- 2026-07-20IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc. - GlobeNewswire
- 2026-07-20Immix Biopharma drops after chief medical officer terminated - MSN
- 2026-07-20Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims - TMX Newsfile
- 2026-07-20Immix Biopharma exec fired following arrest after 20 years on the run - Seeking Alpha
- 2026-07-20Immix Biopharma stock tumbles amid fugitive CMO report - Investing.com
- 2026-07-20Immix Biopharma (IMMX) reports Richard Graydon’s departure as immaterial event - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.